AAV Arms Race: Who Controls Gene Therapy’s Future?

As AAV demand surges, biotech firms race to lock in manufacturing capacity, reshaping alliances and competition across gene therapy

19 Feb 2026

A quiet power shift is underway in North America’s gene therapy sector, and it is happening far from the clinic. Behind the headlines about breakthrough treatments lies a more prosaic reality: whoever controls manufacturing capacity holds the advantage.

At the center of this scramble is adeno-associated virus, or AAV, the workhorse vector for many gene therapies in development. As more programs push deeper into clinical trials, companies are racing to secure the production muscle needed to get treatments to patients. That urgency has turned viral vector manufacturing into one of biotech’s most strategic battlegrounds.

For emerging firms, building in-house facilities is rarely practical. The price tag is steep, the expertise specialized, and the timelines long. Outsourcing to contract development and manufacturing organizations, or CDMOs, offers a faster and often less risky route. The result is a surge in multi-year supply agreements, expanded service deals, and carefully targeted acquisitions designed to lock in access.

Major players are responding in kind. Lonza continues to scale services from early process development through commercial production. WuXi AppTec is investing heavily in integrated platforms and new facilities, while Merck KGaA is sharpening its focus on process consistency and scalable systems within its life science division. Each move reflects the same calculation: demand for AAV is not a passing trend.

Capacity, however, is finite. As production slots tighten, CDMOs gain leverage, particularly for late-stage programs racing toward approval. Companies that hesitate risk delays or higher costs, especially if clinical success rates climb beyond current expectations.

Regulators add another layer of complexity. Viral vector manufacturing faces strict quality and safety standards, and developers tend to favor partners with proven compliance records. A misstep in production can ripple across an entire pipeline.

The market is projected to expand at double-digit rates through 2033, but optimism comes with caution. If scientific breakthroughs outpace manufacturing scale-up, bottlenecks could slow progress. For now, outsourcing offers a pragmatic solution, allowing innovators to focus on science while specialists handle the factory floor.

In the new era of gene therapy, manufacturing is no longer a back-office function. It is strategy, leverage, and increasingly, power.